Chacón RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res. 2010;12(2):S3. https://doi.org/10.1186/bcr2574.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–90. https://doi.org/10.1038/nrclinonc.2016.66. Epub 2016/10/19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430–42. https://doi.org/10.1016/s0140-6736(16)32454-0. Epub 2016/12/13.

Article  CAS  PubMed  Google Scholar 

Early Breast Cancer Trialists’, Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (London England). 2012;379(9814):432–44. https://doi.org/10.1016/S0140-6736(11)61625-5.

Article  CAS  Google Scholar 

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The Triple negative Paradox: primary tumor chemosensitivity of breast Cancer subtypes. Clin Cancer Res. 2007;13(8):2329. https://doi.org/10.1158/1078-0432.CCR-06-1109.

Article  CAS  PubMed  Google Scholar 

Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-Approved Immune Checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738. https://doi.org/10.3390/cancers12030738.

Article  CAS  PubMed  Google Scholar 

Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959–66. https://doi.org/10.1200/jco.2013.55.0491.

Article  PubMed  PubMed Central  Google Scholar 

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer Genome Landscapes Sci. 2013;339(6127):1546. https://doi.org/10.1126/science.1235122.

Article  CAS  Google Scholar 

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361–70. https://doi.org/10.1158/2326-6066.Cir-13-0127. Epub 2014/04/26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with Advanced Triple-negative breast Cancer: phase ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460–7. https://doi.org/10.1200/jco.2015.64.8931.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmid P, Cruz C, Braiteh FS, Eder JP, Tolaney S, Kuter I, et al. Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): long-term clinical outcomes and biomarker analyses. Cancer Res. 2017;77(13 Supplement):2986. https://doi.org/10.1158/1538-7445.AM2017-2986.

Article  Google Scholar 

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-negative breast Cancer. N Engl J Med. 2018;379(22):2108–21. https://doi.org/10.1056/NEJMoa1809615.

Article  CAS  PubMed  Google Scholar 

Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019(a);30(3):405 – 11. https://doi.org/10.1093/annonc/mdy518.

Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study. Ann Oncol 2019(b);30(3):397–404. https://doi.org/10.1093/annonc/mdy517.

Ramakrishnan R, Gabrilovich DI. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol Immunother. 2011;60(3):419–23. https://doi.org/10.1007/s00262-010-0930-1. Epub 2010/10/27.

Article  CAS  PubMed  Google Scholar 

Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, et al. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: a systematic review and meta-analysis. Eur J Cancer. 2021;151:35–48. https://doi.org/10.1016/j.ejca.2021.03.049.

Article  CAS  PubMed  Google Scholar 

Landre T, Chouahnia K, Des Guetz G, Duchemann B, Assié J-B, Chouaïd C. First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920977137. https://doi.org/10.1177/1758835920977137.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang C, Qiao W, Jiang Y, Zhu M, Shao J, Wang T, et al. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cell Physiol. 2020;235(5):4913–27. https://doi.org/10.1002/jcp.29371.

Article  CAS  PubMed  Google Scholar 

Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279–88. https://doi.org/10.1093/annonc/mdz158.

Article  CAS  PubMed  Google Scholar 

Gianni L, Huang C-S, Egle D, Bermejo B, Zamagni C, Thill M, et al. Abstract GS3-04: pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res. 2020;80(4 Supplement):GS3–04. https://doi.org/10.1158/1538-7445.SABCS19-GS3-04.

Article  Google Scholar 

Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–100. https://doi.org/10.1016/s0140-6736(20)31953-x.

Article  CAS  PubMed  Google Scholar 

Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete response in women with early-stage breast Cancer: an analysis of the Ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676–84. https://doi.org/10.1001/jamaoncol.2019.6650.

Article  PubMed  Google Scholar 

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast Cancer. N Engl J Med. 2020;382(9):810–21. https://doi.org/10.1056/NEJMoa1910549.

Article  CAS  PubMed  Google Scholar 

Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59. https://doi.org/10.1016/s1470-2045(19)30689-8.

Article  CAS  PubMed  Google Scholar 

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–28. https://doi.org/10.1016/S0140-6736(20)32531-9.

Article  PubMed  Google Scholar 

Miles DW, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios CH, et al. LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Annals of Oncology.2020;31:S1147-S8. https://doi.org/10.1016/j.annonc.2020.08.2243.

Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, et al. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nat Med. 2022;28(12):2573–83.

Article  PubMed  PubMed Central  Google Scholar 

Florez MA, Kemnade JO, Chen N, Du W, Sabichi AL, Wang DY, et al. Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access. Cancer Res Commun. 2022;2022(8):806–13.

Article  PubMed  Google Scholar 

Yan X, Tian X, Wu Z, Han W. Impact of age on the efficacy of Immune Checkpoint inhibitor-based combination therapy for non-small-cell lung Cancer: a systematic review and Meta-analysis. Front Oncol. 2020;10:1671.

Article  PubMed  PubMed Central